Page last updated: 2024-09-04

tipifarnib and Neoplasms

tipifarnib has been researched along with Neoplasms in 36 studies

Research

Studies (36)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.78)	18.2507
2000's	31 (86.11)	29.6817
2010's	4 (11.11)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bell, IM	1
Merkus, D; Schermuly, RT	1
Adjei, A; Allred, J; Goetz, M; Jazieh, K; Kaufmann, SH; Lim, VS; Molina, J; Reid, J; Yin, J	1
Fernandes, PA; Moorthy, NS; Ramos, MJ; Sousa, SF	1
Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L	1
Chandhasin, C; Kurzrock, R; Tsimberidou, AM	1
Cheson, BD; Gravell, AE; Wright, JJ; Zerivitz, K	1
Adjei, AA; Dy, GK; Haluska, P	1
Bonginelli, P; Capaccetti, B; Fanelli, M; Gasparini, G; Gattuso, D; Longo, R; Sarmiento, R	1
Nishiyama, M; Tahara, E; Tsuruo, T; Yasui, W	1
Angibaud, P; End, D; Venet, M	1
Adjei, AA; Alberts, SR; Atherton, P; Bruzek, LM; Croghan, GA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Marks, RS; Palmer, PA; Pitot, HC; Reid, JM; Sloan, JA; Thibault, A	1
Eckhardt, SG; Gentner, L; Goetz, A; Hammond, LA; Izbicka, E; McCreery, H; Mori, M; Patnaik, A; Richards, H; Rowinsky, EK; Rybak, ME; Schwartz, G; Takimoto, CH; Terada, K; Tolcher, AA; Zhang, S	1
Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P	1
de Bruijn, P; de Heus, G; de Jonge, MJ; Eskens, FA; Kehrer, DF; Klaren, A; Mathijssen, RH; Palmer, PA; Planting, AS; Sparreboom, A; Verhaeghe, T; Verheij, C; Verweij, J; Xie, R; Zhang, S	1
Marsh, S; Mathijssen, RH; McLeod, HL; Sparreboom, A; Verweij, J	1
Doroshow, JH; Frankel, P; Gandara, DR; Gumerlock, PH; Kawaguchi, T; Lara, PN; Lau, DH; Law, LY; Lenz, HJ; Twardowski, P; Wright, JJ	1
Helbig, G; Hołowiecki, J	1
Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Marra, M; Tagliaferri, P	1
Kurzrock, R	1
Beijnen, JH; Crul, M; Howes, A; Pluim, D; Schellens, JH; Siegel-Lakhai, WS; Solanki, B; Sparidans, RW; Zhang, S	1
Mesa, RA	1
Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN	1
De Porre, P; Hayes, S; Perez-Ruixo, JJ; Piotrovskij, V; Zannikos, P; Zhang, S	1
Cohen, RB; Eckhardt, SG; Gore, L; Gustafson, D; Holden, SN; Mikule, C; Morrow, M; O'Bryant, CL; Palmer, PA; Persky, M; Pierson, AS; Zhang, S	1
Awada, A; De Porre, P; Dirix, LY; Francois, M; Fumoleau, P; Piccart-Gebhart, M; Verhaeghe, T; Zannikos, P; Zhang, S	1
Beijnen, JH; Boot, H; Chang, I; Crul, M; De Porre, P; Schellens, JH; Siegel-Lakhai, WS; Zhang, S	1
Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S	1
Abbruzzese, A; Arra, C; Baldi, A; Barbieri, A; Budillon, A; Caraglia, M; D'Alessandro, AM; Marra, M; Meo, G; Rapp, UR; Tagliaferri, P; Tassone, P; Venuta, S; Viscomi, C	1
Blatner, GL; Cheson, BD; Wright, J	1
Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J	1
Bol, CJ; Punt, CJ; Seifert, WF; van Maanen, L; Wagener, DJ	1
Gabrilove, JL	1
Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ	1
Norman, P	1
Beijnen, JH; Boerrigter, L; Bol, CJ; Crul, M; de Gast, GC; de Jong, D; de Klerk, GJ; Palmer, PA; Schellens, JH; Swart, M; Tan, H; van't Veer, LJ	1

Reviews

14 review(s) available for tipifarnib and Neoplasms

Article	Year
Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? Journal of medicinal chemistry, 2004, Apr-08, Volume: 47, Issue:8 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Design; Farnesyltranstransferase; Genes, ras; Humans; Neoplasms	2004
Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis. Current medicinal chemistry, 2013, Volume: 20, Issue:38 Topics: Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Pyridines; Quantitative Structure-Activity Relationship; Quinolones	2013
Farnesyltransferase inhibitors: where are we now? Expert opinion on investigational drugs, 2010, Volume: 19, Issue:12 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Neoplasms; Quinolones	2010
Farnesyl transferase inhibitors as anticancer agents. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:13 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Neoplasms; Piperidines; Pyridines; Quinolones; Tumor Cells, Cultured	2002
[Innovative treatment in oncology]. Recenti progressi in medicina, 2002, Volume: 93, Issue:11 Topics: Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinolones	2002
Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery. Current topics in medicinal chemistry, 2003, Volume: 3, Issue:10 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Mice; Molecular Structure; Neoplasms; Protein Prenylation; Quinolones; Structure-Activity Relationship	2003
[Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2004, Volume: 57, Issue:9-10 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Genes, ras; GTP-Binding Proteins; Guanosine Triphosphate; Humans; Imidazoles; Neoplasms; Piperidines; Point Mutation; Pyridines; Quinolones; Signal Transduction	2004
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Current drug targets, 2005, Volume: 6, Issue:3 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; Neoplasms; Phosphatidylinositol 3-Kinases; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; ras Proteins	2005
Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert review of anticancer therapy, 2006, Volume: 6, Issue:3 Topics: Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Treatment Outcome	2006
[Problems in the current target therapy of malignancies]. Voprosy onkologii, 2005, Volume: 51, Issue:5 Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab	2005
Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. British journal of clinical pharmacology, 2006, Volume: 62, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Quinolones; Tablets	2006
Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes. Seminars in hematology, 2001, Volume: 38, Issue:3 Suppl 7 Topics: Alkyl and Aryl Transferases; Anemia; Enzyme Inhibitors; Erythropoietin; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Recombinant Proteins	2001
Current status of clinical trials of farnesyltransferase inhibitors. Current opinion in oncology, 2001, Volume: 13, Issue:6 Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction	2001
Tipifarnib (Janssen Pharmaceutica). Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:2 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Ataxia; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drugs, Investigational; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Structure-Activity Relationship; Thrombocytopenia; Treatment Outcome	2002

Trials

16 trial(s) available for tipifarnib and Neoplasms

Article	Year
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Investigational new drugs, 2019, Volume: 37, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinolones; Salvage Therapy; Tissue Distribution	2019
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-15, Volume: 15, Issue:22 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome	2009
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors	2003
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Models, Chemical; Neoplasms; Protein Prenylation; Quinolones; ras Proteins; Time Factors; Treatment Outcome	2003
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:6 Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones	2004
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. British journal of cancer, 2004, Apr-19, Volume: 90, Issue:8 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Treatment Outcome	2004
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Humans; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Quinolones; Tandem Repeat Sequences	2004
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anti-cancer drugs, 2005, Volume: 16, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; California; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Protein Prenylation; Quinolones	2005
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. British journal of cancer, 2005, Nov-28, Volume: 93, Issue:11 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones	2005
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:11 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Prenylation; Quinolones	2006
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer. Journal of clinical pharmacology, 2006, Volume: 46, Issue:10 Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Glucuronides; Glycoproteins; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Binding; Quinolones; Serum Albumin; Tablets; Treatment Outcome	2006
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28 Topics: Adult; Aged; Area Under Curve; Farnesyltranstransferase; Female; Humans; Liver; Male; Middle Aged; Models, Statistical; Neoplasms; Neutrophils; Quinolones; Time Factors	2006
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies. Current medical research and opinion, 2007, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Female; Humans; Immune System; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Taxoids; Treatment Outcome	2007
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4 Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Anemia; Biological Availability; Bone Marrow; Capsules; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Half-Life; Headache; Humans; Hypotension; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Peripheral Nervous System Diseases; Quinolones; Solutions; Vomiting	2000
Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anti-cancer drugs, 2001, Volume: 12, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Biological Availability; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Quinolones; Time Factors; Vomiting	2001
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-01, Volume: 20, Issue:11 Topics: Administration, Oral; Alkyl and Aryl Transferases; Antineoplastic Agents; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Genes, ras; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Nausea; Neoplasms; Quinolones; Vomiting	2002

Other Studies

6 other study(ies) available for tipifarnib and Neoplasms

Article	Year
Farnesylation of RhoB: the cancer hypothesis of pulmonary hypertension revisited. Cardiovascular research, 2017, 03-01, Volume: 113, Issue:3 Topics: Humans; Hypertension, Pulmonary; Hypoxia; Neoplasms; Prenylation; Quinolones; rhoB GTP-Binding Protein	2017
Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra). Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:7 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Humans; Mice; Neoplasms; Quinolones; Transplantation, Heterologous	2002
Molecular targeting therapy for cancer: the Twelfth International Symposium of the Hiroshima Cancer Seminar, November 2002. Cancer science, 2003, Volume: 94, Issue:2 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials as Topic; DNA Repair; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Farnesyltranstransferase; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Proteins; Neoplasms; Quinolones; Xenograft Model Antitumor Assays	2003
Farnesyltransferase inhibitors. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:3 Topics: Acylation; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Middle Aged; Neoplasm Proteins; Neoplasms; Protein Processing, Post-Translational; Quinolones; ras Proteins; Treatment Outcome	2005
The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. International journal of cancer, 2007, Nov-15, Volume: 121, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Farnesyltranstransferase; Female; Humans; Immunohistochemistry; Interferon-alpha; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Phosphoserine; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Quinolones; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays	2007
Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:11 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Neoplasms; Quinolones	1999